Publications

Journal Articles

  1. et. al. Health-related quality of life results from the phase III CheckMate 067 study. European Journal of Cancer 82, 80-91.
  2. et. al. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. Journal of Clinical Oncology 35(14), 1530-1541.
  3. et. al. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. European Urology
  4. et. al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. New England Journal of Medicine
  5. et. al. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. European Urology
  6. et. al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet
  7. & Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Annals of Oncology 27(1), 159-165.
  8. et. al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine 373(19), 1803-1813.
  9. et. al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine 373(1), 23-34.
  10. Treatment patterns, outcomes, and resource utilisation of patients with metastatic melanoma in the U.K.: the MELODY study. British Journal of Dermatology, e12503
  11. et. al. A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). European Journal of Cancer 49(16), 3507-3516.
  12. & Drivers and barriers to patient participation in RCTs. British Journal of Cancer 108(7), 1402-1407.
  13. & Teams talking trials: results of an RCT to improve the communication of cancer teams about treatment trials. Contemporary Clinical Trials 35(1), 51
  14. & A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer 49(6), 1287-1296.
  15. & Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treatment Reviews 38(2), 127-132.
  16. Optimizing treatment for metastatic renal cell carcinoma. Expert Review of Anticancer Therapy
  17. & Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice.. Cancer Investigation 28, 856-864.
  18. & Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology 28(6), 1061-1068.
  19. & Amino acid derivatives from Lucilia sericata ES may contribute to the beneficial effects of maggot therapy via increased angiogenesis.. British Journal of Dermatology 162, 554-562.
  20. & Ibandronate reduces endogenous reactive oxygen species levels in cultured prostate cancer and endothelial cells. Microvascular Research 78(2), 141-141.
  21. & Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. Microvascular Research 78, 453-458.
  22. & Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?. Acta Oncologica 48, 882-889.
  23. & UK guidelines for the systemic treatment of renal cell carcinoma. British Journal of Hospital Medicine 70, 284-286.